Key Developments: Peregrine Pharmaceuticals Inc (PPHM.O)

PPHM.O on Consolidated Issue listed on NASDAQ Capital Market

1.43USD
21 Nov 2014
Price Change (% chg)

$0.02 (+1.42%)
Prev Close
$1.41
Open
$1.43
Day's High
$1.45
Day's Low
$1.41
Volume
541,229
Avg. Vol
1,027,371
52-wk High
$3.18
52-wk Low
$1.24

Search Stocks

Latest Key Developments (Source: Significant Developments)

Peregrine Pharmaceuticals, Inc reaffirms FY 2015 guidance
Tuesday, 9 Sep 2014 04:00pm EDT 

Peregrine Pharmaceuticals, Inc:Expects contract manufacturing revenue for FY 2015 to be between $19 and $23 million.  Full Article

Peregrine Pharmaceuticals Inc declares quarterly dividend on its series E convertible preferred stock
Monday, 8 Sep 2014 04:00pm EDT 

Peregrine Pharmaceuticals Inc:Declares quarterly cash dividend payment on company's 10.50 pct Series E Convertible Preferred Stock.Payable on Oct. 01 to holders of record on Sept. 19.  Full Article

Peregrine Pharmaceuticals Inc announces preclinical data shows combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression
Monday, 11 Aug 2014 08:00am EDT 

Peregrine Pharmaceuticals Inc:Says preclinical data further validating potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform.Results show that combination of PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression.Says while also demonstrating significant increase in tumor-fighting T-cells into tumor microenvironment compared to anti-PD-1 antibody treatment alone in immune competent animal model of breast cancer.Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.Says these data further validate that blocking the immunosuppressive effects of PS facilitate an increase in tumor-fighting T-cells, and that the combination with PD-1 then allows for a more effective anti-tumor T-cell response.  Full Article

Peregrine Pharmaceuticals Inc gives FY 2015 revenue guidance below analysts' estimates - Conference Call
Monday, 14 Jul 2014 04:30pm EDT 

Peregrine Pharmaceuticals Inc:Expects FY 2015 contract manufacturing revenue to be between $19 million and $23 million.FY 2015 revenue of $24 million - Thomson Reuters I/B/E/S.  Full Article

Peregrine Pharmaceuticals declares quarterly dividend on Series E convertible preferred stock
Tuesday, 10 Jun 2014 04:00pm EDT 

Peregrine Pharmaceuticals Inc:Declares a quarterly cash dividend payment on the company's 10.50 pct Series E Convertible Preferred Stock.Payable on July 1 to holders of record at the close of business on June 20.Quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share.  Full Article

Peregrine Pharmaceuticals Inc announces initiation of investigator-sponsored trial combining its Immunotherapy Bavituximab and Ipilimumab (Yervoy) in Advanced Melanoma
Wednesday, 23 Apr 2014 07:30am EDT 

Peregrine Pharmaceuticals Inc:Opening of investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy), for treatment of advanced melanoma.Bavituximab is upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells.Preclinical data in model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone.Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer (NSCLC), as part of SUNRISE pivotal Phase III clinical trial.  Full Article

Peregrine Pharmaceuticals Inc presents data on bavituximab at AACR
Wednesday, 9 Apr 2014 11:00am EDT 

Peregrine Pharmaceuticals Inc:Presents data from studies validating immune-stimulatory mechanism of action of bavituximab.Demonstrating that combination of preclinical phosphatidylserine (PS)-targeting antibody with immune checkpoint inhibitors anti-CTLA-4 or anti-PD-1 antibodies yielded superior anti-tumor immune responses in animal models of melanoma.Says colon cancer compared to anti-CTLA-4 and PD-1 antibodies alone.Bavituximab is investigational immunotherapy being evaluated in second-line, non-small cell lung cancer (NSCLC) as part of SUNRISE pivotal Phase III clinical trial.Data from these combination studies are compelling as they provide further evidence that support immune-stimulatory effects of bavituximab in reducing prevalence of key immunosuppressive checkpoints in tumor environment.Reducing tumor-suppressive factors, reducing immune suppressor cells and providing increased tumor-specific immunity.These data also show that when combined with downstream immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1, PS targeting mediates improved protective tumor-specific immunity following tumor rechallenge.  Full Article

Peregrine Pharmaceuticals Inc updates progress in investigator-sponsored phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Friday, 14 Mar 2014 08:00am EDT 

Peregrine Pharmaceuticals Inc:Presentation of update to ongoing Investigator-Sponsored Trial (IST) of immunotherapy bavituximab in combination with the chemotherapy sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma (HCC) or liver cancer.Phase II portion of this trial is ongoing with 34 of 38 intended patients enrolled, 10 of which are on treatment with longest one on treatment for 18 months.This open-labeled trial is almost complete and while the results are preliminary, they are promising.Phase II portion of this trial is a single-center, single-arm, non-randomized, open-label trial with the primary endpoint of radiologic time to progression with imaging occurring at 6 week intervals.Secondary endpoints of trial include overall survival (OS), progression free survival (PFS), safety and response rates.Trial is scheduled to enroll 38 patients with advanced liver cancer.In order to leverage recent understandings surrounding the immune-stimulatory mechanism of action of bavituximab, several additional components have been installed into this portion of the trial.These include plasma and serum collection and tissue biopsies for evaluating changes in immune response following bavituximab treatment.Specifically, to assess whether combination therapy reactivates tumor immunity by changing the tumor microenvironment from immunosuppressive to immunoreactive, changing the tumor infiltrating cell composition or inducing T cell response to tumor antigens.  Full Article

Peregrine Pharmaceuticals Inc declares quarterly dividend on its series E convertible preferred stock
Tuesday, 11 Mar 2014 04:10pm EDT 

Peregrine Pharmaceuticals Inc:Declares a quarterly cash dividend on the company's 10.50 pct Series E Convertible Preferred Stock.Payable on Apr. 1 to holders of record at the close of business on Mar. 21.  Full Article

Peregrine Pharmaceuticals Inc reaffirms FY 2014 revenue outlook
Friday, 7 Mar 2014 08:00am EST 

Peregrine Pharmaceuticals Inc:Says it on track to be on the higher end of previously stated guidance for FY 2014 revenue of $18 and $22 mln.FY 2014 revenue of $22 mln - Thomson Reuters I/B/E/S.  Full Article

Search Stocks